A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment

Neurology

Volumn 50, Issue 3, 1998, Pages 645-651

  Sacktor, Ned ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; SELEGILINE; THIOCTIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERBAL MEMORY;

EID: 0344813768     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.3.645     Document Type: Article

References (52)

1. Levy RM, Bredesen DE, Rosenblum NL. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985;62:475-495.
2. McArthur JC. Neurologic manifestations of AIDS. Medicine 1987;66:407-437.
3. Janssen RS, Cornblath DR, Epstein LG, et al. Nomeclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778-785.
4. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993;43: 2245-2252.
5. Portegies P, Enting RH, Degans J, et al. Presentation and course of AIDS dementia complex: ten years of follow-up in Amsterdam, the Netherlands. AIDS 1993;7:669-675.
6. Navia BA, Jordan BD, Price RW. The AIDS dementia complex. I. Clinical features. Ann Neurol 1986;19:517-524.
7. Bouwman FH, Skolasky RL, Dal Pan G, et al. Variation in clinical progression of HIV-associated dementia. XI International Conference on AIDS, Vancouver, British Columbia, 1996.
8. McArthur JC, Grant I. HIV neurocognitive disorders. In: Gendelman HE, Lipton S, Epstein L, Swindell S, eds. Neurological and Neuropsychiatric manifestations of HIV-1 infection. New York: Chapman and Hall, 1998.
9. Yarchoan R, Berg G, Brouwers P, et al. Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987;1:132-135.
10. Schmitt FA, Bigley JWS, McKinnis R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988;319: 1573-1578.
11. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 1993;33:343-349.
12. Yarchoan R, Pluda JM, Thomas RV, et al. Long-term toxicity/ activity profile of 2′,3′-dideoxyinosine in AIDS and AIDS-related complex. Lancet 1990;336:526-529.
13. Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol 1993;33:429-436.
14. Lipton SA, Gendelman HE. The dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995; 332:934-940.
15. Coyle JT, Puttfarken P. Oxidative stress, glutamate and neurodegenerative disorders. Science 1993;262:698-700.
16. Gelbard HA, James H, Sharer LR, et al. Apoptotic neurons in brains from pediatric patients with HIV-1 encephalitis and progressive encephalopathy. Neuropathol Appl Neurobiol 1995;21:208-217.
17. Adle-Biasette H, Levy Y, Colombel M, et al. Neuronal apoptosis in HIV infection in adults. Neuropathol Appl Neurobiol 1995;21:218-227.
18. Ansari KS, Yu PH, Kruck TPA, Tatton WG. Rescue of axotomized immature rat facial motorneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053.
19. Tatton WG, Ju WYH, Holland DP, Tai C, Kwan M. (-)Deprenyl reduced PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
20. Tatton WG. Selegiline can mediate neuronal rescue rather than neuronal protection. Move Dis 1993;8:520-530.
21. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47(Suppl 3):S171-183.
22. Kagan VE, Shvedova A, Serbinova E, et al. Dihydrolipoic acid - a universal antioxidant both in the membrane and in the aqueous phase. Biochem Pharmacol 1992;44:1637-1649.
23. Packer L, Suzuki YJ. Vitamin E and alpha-lipoate: role in antioxidant recycling and activation of the NF-MB transcription factor. Mol Aspects Med 1993;14:229-239.
24. Concha M, Selnes OA, McArthur JC, et al. Normative data for a brief neuropsychologic test battery in a cohort of injecting drug users. Int J Addict 1995;30:823-841.
25. Selnes OA, Jacobson L, Machado AM, et al. Normative data for a brief neuropsychological screening battery. Percept Mot Skills 1991;73:539-550.
26. Karnofsky DA, Abelman WH, Carver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-656.
27. Rey A. L'examen Psychologique dans les cas d'enchephalopathie traumatique. Arch Psychol 1941;28:286-340.
28. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Corporation, 1981.
29. Klove H. Clinical neuropsychology. Med Clin North Am 1963; 46:1647-1658.
30. Miller EN, Satz P, Visscher B. Computerized and conventional neuropsychological assessment of HIV-1 infected homosexual men. Neurology 1991;41:1608-1616.
31. Katz S, Ford A, Moskowit R, et al. Studies of illness in the aged: The index of ADL. JAMA 1963;183:914-919.
32. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
33. Stewart AL, Ware JE. Measuring function and well-being: the Medical Outcomes Study Approach. Durham, NC: Duke University Press, 1993.
34. Radloff LL. The CES-D: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1: 385-401.
35. Fahn S, Marsden C, Caine D. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information, 1987:153.
36. Agresti A. Categorical data analysis. New York: Wiley, 1990.
37. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079-1083.
38. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Safety and tolerability of the antioxidant OPC-14,117 in HIV associated cognitive impairment. Neurology 1997;49:142-146.
39. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
40. Finali G, Piccirilli M, Oliano G, et al. L-Deprenyl therapy improves verbal memory in amnesic Alzheimer's patients. Clin Neuropharmacol 1991;14:523-536.
41. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegilene, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
42. Kieburtz K, McDermott M, Como P, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology 1994;44:1756-1759.
43. Knoll J. The possible mechanism of action of (-)deprenyl in Parkinson's disease. J Neural Transm 1978;43:177-198.
44. Mytilineou C, Radcliffe P, Leonardi EK, et al. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 1997;68:33-39.
45. Tatton W, Ju W, Wadia J, et al. (-)-Deprenyl reduces neuronal apoptosis by maintaining bcl-2 synthesis and mitochondrial membrane potential. Mov Dis 1994;9:4.
46. Biagini G, Frasoldati A, Fuxe K, et al. The concept of astrocyte-kinetic drug in the treatment of neurodegenerative disease: evidence for L-deprenyl-induced activation of reactive astrocytes. Neurochem Int 1994;25:17-22.
47. Seniuk NA, Henderson JT, Tatton WG, Roder JC. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J Neurosci Res 1994; 37:278-286.
48. Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of L-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 1993; 243:241-247.
49. Chiueh CC, Huang SJ, Murphy DL. Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuro-protective mechanism in dopaminergic neurotoxicity. J Neural Transm Suppl 1994;41:189-196.
50. Carrillo MC, Ivy GO, Milgram NW, et al. (-)L-Deprenyl increases activities of superoxide dismutase (SOD) in striatum of dog brain. Life Sci 1994;54:1483-1489.
51. Thiffault C, Aumont N, Quiron R, Poirier J. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem 1995;65:2725-2733.
52. Knoll J, Miklya I, Knoll B, Marko R, Kelemen K. (-)Deprenyl and (-)L-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci 1996;58:817-827.